Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ethinylestradiol/gestodene transdermal

Drug Profile

Ethinylestradiol/gestodene transdermal

Alternative Names: APLEEK; BAY86-5016; Estrogen/gestagen transdermal; Ethinylestradiol/gestodene transparent low dose contraceptive patch - Bayer HealthCare; FC Patch Fidencia; FC Patch Low; FC-patch; Fertility Control patch; Gestagen/estrogen transdermal; Gestodene/EE Patch; Gestodene/ethinylestradiol transdermal; Lisvy

Latest Information Update: 05 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer Schering Pharma
  • Developer Bayer HealthCare Pharmaceuticals; Gedeon Richter
  • Class Alkylated estrogenic steroids; Norpregnatrienes; Norpregnenes
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Pregnancy

Most Recent Events

  • 05 Jul 2019 Ethinylestradiol/gestoden is not yet available for Pregnancy (Prevention) in Spain, Italy, Italy, Netherlands, Germany, Lithuania, Denmark, Slovenia, Finland, Belgium, Ireland, Slovakia, Romania, Portugal, Iceland, Czech Republic, Malta, Greece, Austria (Transdermal)
  • 05 Jul 2019 Launched for Pregnancy (Prevention) in Spain, Czech Republic, Hungary, Spain prior July 2019 (Transdermal)
  • 06 Aug 2018 Luye Pharma acquires global rights for Ethinylestradiol/gestodene from Bayer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top